SCHEMBL30228177

SCHEMBL30228177

Nc1ccc2c(-c3ccc(F)cc3Cl)cc(=O)oc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ HPGD P15428 4/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ GAA P10253 2/20 0.49
▸ CASP1 P29466 2/20 0.49
▸ CASP7 P55210 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ SRC P12931 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ TLR9 Q9NR96 1/20 0.49
▸ CA12 O43570 7/20 0.49
▸ CA9 Q16790 7/20 0.49
▸ GLA P06280 2/20 0.49
▸ CA1 P00915 1/20 0.49
▸ TDO2 P48775 1/20 0.39
▸ GRM2 Q14416 2/20 0.38
▸ KCNA3 P22001 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228226 0.84 CA12 (0.69) KDM4EALDH1A1HPGDKMT2AGAA
SCHEMBL20839408 0.84 CA12 (0.69) KDM4EALDH1A1HPGDKMT2AGAA
SCHEMBL30228096 0.84 CA12 (0.48) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL30227956 0.84 CA12 (0.48) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL31089799 0.82 CA12 (0.51) KDM4EALDH1A1HPGDCA12CA9
SCHEMBL30228063 0.82 CA12 (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL26114135 0.81 CA12 (0.69) KDM4EALDH1A1HPGDKMT2AGAA
SCHEMBL30228256 0.81 MEN1 (0.49) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL30228386 0.81 CA12 (0.45) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL30227943 0.81 CA12 (0.45) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM KDM4E 2158/4885ALDH1A1 3178/4885HPGD 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback